Format

Send to

Choose Destination
J Urol. 2014 Jul;192(1):230-4. doi: 10.1016/j.juro.2014.01.113. Epub 2014 Feb 25.

Detection of prostate cancer by an electronic nose: a proof of principle study.

Author information

1
School of Medicine, University of Tampere, Tampere, Finland. Electronic address: antti.roine@uta.fi.
2
Department of Surgery, School of Medicine, University of Tampere and Department of Urology, Tampere University Hospital, Tampere, Finland.
3
School of Medicine, University of Tampere, Tampere, Finland.
4
Department of Automation Science and Engineering, Tampere University of Technology, Tampere, Finland.
5
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
6
School of Pharmacy, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland.
7
Department of Pathology, School of Medicine, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
8
Department of Clinical Chemistry, Fimlab Laboratories and University of Tampere, School of Medicine, Tampere, Finland.
9
Department of Surgery, School of Medicine, University of Tampere and Department of Vascular Surgery, Tampere University Hospital, Tampere, Finland.

Abstract

PURPOSE:

We evaluate the ability of an electronic nose to discriminate prostate cancer from benign prostatic hyperplasia using urine headspace, potentially offering a clinically applicable noninvasive and rapid diagnostic method.

MATERIALS AND METHODS:

The ChemPro® 100-eNose was used to discriminate prostate cancer from benign prostatic hyperplasia using urine sample headspace. Its performance was tested with 50 patients with confirmed prostate cancer and 24 samples from 15 patients with benign prostatic hyperplasia (15 patients provided urine preoperatively and 9 patients provided samples 3 months postoperatively) scheduled to undergo robotic assisted laparoscopic radical prostatectomy or transurethral resection of prostate, respectively. The patients provided urine sample preoperatively and those with benign prostatic hyperplasia also provided samples 3 months postoperatively to be used as a pooled control sample population. A discrimination classifier was identified for eNose and subsequently, sensitivity and specificity values were determined. Leave-one-out cross-validation was performed.

RESULTS:

Using leave-one-out cross-validation the eNose reached a sensitivity of 78%, a specificity of 67% and AUC 0.77.

CONCLUSIONS:

The electronic nose is capable of rapidly and noninvasively discriminating prostate cancer and benign prostatic hyperplasia using urine headspace in patients undergoing surgery.

KEYWORDS:

electronic nose; prostatic hyperplasia; prostatic neoplasms

Comment in

PMID:
24582536
DOI:
10.1016/j.juro.2014.01.113
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center